PTGER4 and neoplasm: These data indicate that in vivo the effects of E7046 in EP4 signaling blockade are both systemic, affecting the myeloid cells in both tumor and spleen, and dynamic: reducing the intra-tumoral immunosuppressive MDSCs and M2-like TAMs relatively early after treatment initiation, and promoting intra-tumoral T cell accumulation later during treatment.